Treatment of High Output Chyle Leak After Left Chest Procedures

Initial Management

The American College of Radiology recommends confirming diagnosis through pleural fluid analysis with diagnostic criteria including pleural fluid triglyceride level >110 mg/dL and ratio of pleural fluid to serum triglyceride level >1.0 1
Initial drainage of chylous fluid provides both diagnostic confirmation and symptom relief 1
Replacement of fluid and protein losses is necessary to maintain nutritional status, as 1000 mL of chyle may contain up to 30 g of protein 2

The American College of Radiology suggests beginning with conservative measures for initial management of chyle leak 1, 3
Dietary modifications, such as a diet low in long-chain triglycerides (<5% of total energy intake) and enrichment with medium-chain triglycerides (>20% of total energy intake), are recommended 2
Adjunctive pharmacological therapy, including somatostatin and etilefrine, may be used to reduce lymphatic flow 1, 3
Conservative success rates approach 50% in nonmalignant etiologies but are less effective in neoplastic etiologies 1, 3

Invasive treatment should be considered if conservative management fails after 2 weeks 1, 3
High output (>500-1000 mL/day) is a key indicator for more aggressive management 2
A step-up approach is recommended, with TPN and consideration of invasive intervention for outputs >1000 mL/day 2

The American College of Radiology recommends TDE as first-line invasive treatment for high output chyle leaks 3, 4
Technical success rates of 85-88.5% across all causes have been reported 3, 4
Clinical success rates of up to 97% for nontraumatic chylous effusions have been achieved 3
Complications are generally minor (2-6%) and self-limited 3

Thoracic duct ligation may be considered if TDE fails or is not available 1, 3
Higher postoperative mortality rates (4.5-50%) compared to TDE have been reported 3

Imaging with lymphangiography or MR lymphangiography can help identify the site of leakage for targeted treatment 5

The American Gastroenterological Association recommends a low long-chain triglycerides diet with medium-chain triglyceride enrichment for initial conservative management of chyle leaks, with protein and electrolyte replacement, as 1000 mL chyle contains up to 30 g protein 6
Octreotide can be initiated when conservative management fails after 2 weeks, or in cases of high-output leak (>500-1000 mL/day), or progressive nutritional depletion, at a dose of 100 μg subcutaneously three times daily, as recommended by the American Gastroenterological Association 6
An alternative dosing regimen of 50 μg subcutaneously twice daily has been reported in the literature to be effective for reducing intestinal output 7

Octreotide can cause side effects such as hyperglycemia, as reported by the Journal of the National Comprehensive Cancer Network 8
Abdominal pain is also a potential side effect of octreotide, as reported in the journal Gut 7

The Journal of the National Comprehensive Cancer Network recommends that octreotide should not be used in insulinomas, as it can suppress counterregulatory hormones and precipitate fatal hypoglycemia 8
Octreotide does not decrease pancreatic fistula rates after pancreatic resection, according to two prospective randomized controlled trials, and should not be used prophylactically for this indication, as reported by the Journal of the National Comprehensive Cancer Network and Clinical Nutrition 9, 6